Many conditions predispose to the development of AOE. Among the most common risk factors is prolonged exposure to water, from swimming or other water-based activities, or through long-term exposure to ...

Otiprio is a sterile, preservative-free, otic suspension that is administered as a single-dose to the external ear canal of each affected ear by a healthcare professional. The approval was based on a ...

Swimmer's ear, or acute otitis externa (AOE), is an inflammation or infection of the external auditory canal that may or may not include the auricle. [1] It is a common health problem that is seen ...

Acute external otitis or otitis externa – more commonly called swimmer’s ear – is an infection that affects the outer ear canal, the section outside your eardrum. It was given the name “swimmer’s ear” ...

Otitis externa, or swimmer’s ear, is inflammation and irritation in the outer ear. People can treat mild cases with antibiotic drops, but infectious cases may need oral antibiotic medication.

ALEXANDRIA, VA — With one in every 123 people in the United States affected by Acute Otits Externa or "swimmer's ear" each year, the American Academy of Otolaryngology—Head and Neck Surgery Foundation ...

The U.S. Food and Drug Administration today approved Xtoro (finafloxacin otic suspension), a new drug used to treat acute otitis externa, commonly known as swimmer's ear. Acute otitis externa is an ...

Zinotic ES available for acute otitis externa Zinotic ES (chloroxylenol, pramoxine HCl and zinc acetate, from Arbor Pharmaceuticals) is now available for the treatment of acute otitis externa (AOE), ...

The US Food and Drug Administration (FDA) has approved Otonomy, Inc's Otiprio (ciprofloxacin otic suspension) 6% for the treatment of acute otitis externa (AOE) in patients 6 months of age and older ...

As the summer vacation season begins in earnest, many people enjoy water activities. However, during the vacation season, the number of patients visiting otolaryngology clinics due to ear pain after ...

SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the signing ...